FFC claims Allergan’s complaint violates anti-SLAPP laws
17-08-2015
360b / Shutterstock.com
Pharmaceutical company Allergan has survived an attempt by hedge fund Ferrum Ferro Capital (FFC) to invalidate a patent covering its Combigan (brimonidine and timolol) drug after the Patent Trial and Appeal Board (PTAB) opted not to institute an inter partes review (IPR).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Ferrum Ferro Capital; Allergan; PTAB; IPR; USPTO; Combigan; glaucoma